Current Illinois CancerCare Clinical Trials

Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery (Just In Time Trial)

Study Number: S1701

Study Summary:
This randomized phase II trial studies how well carboplatin and paclitaxel with or without ramucirumab work in treating patients with thymic cancer that has spread to other places in the body, has come back, or cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as ramucirumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known if giving carboplatin and paclitaxel with or without ramucirumab will work better in treating patients with thymic cancer.

Status: Open

Just in time trial; not currently open at site, but can open quickly if we have a potential

Study Coordinator(s)
  • Navigator Ashton, 309-243-3611
  • Amanda , 309-243-3663,
  • Jessica, 309-243-3615,

Study Link

« Search Again